Moderna files for FDA authorization of its COVID-19 vaccine for adolescents

Moderna said June 10 it has requested emergency use authorization from the FDA for its COVID-19 vaccine for use in children ages 12 to 17. 

The drugmaker already filed for approval for the age group in Canada and Europe. 

In a study of nearly 2,500 kids aged 12 to 17, the vaccine was 100 percent effective against COVID-19. Moderna said it was also 93 percent effective against mild disease 14 days after a single dose. 

No significant safety concerns were discovered in the trial, and the most common side effect was injection site pain.

Read Moderna's full news release here


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like